1. Lassere MN: The biomarker-surrogacy evaluation schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. Stat Methods Med Res. 2008, 17: 303-340.
2. Committee on Qualification of Biomarkers and Surrogate Endpoints: Evaluation of biomarkers and surrogate endpoints in chronic disease. Appendix A. 2010, Washington: The National Academies Press, IOM (Institute of Medicine) DC; 2010
3. Boissel JP, Collet JP, Moleur P, Haugh M: Surrogate endpoints: a basis for a rational approach. Eur J Clin Pharmacol. 1992, 43: 235-244. 10.1007/BF02333016.
4. Lassere MN, Johnson KR, Boers M, Tugwell P, Brooks P, Simon L, Strand V, Conaghan PG, Ostergaard M, Maksymowych WP, Landewe R, Bresnihan B, Tak PP, Wakefield R, Mease P, Bingham CO, Hughes M, Altman D, Buyse M, Galbraith S, Wells G: Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J Rheumatol. 2007, 34: 607-615.
5. Lassere MN: The Innovative Evaluation Schema of Validating Putative Surrogate Endpoints. Joint Statistical Meetings. Vancouver, Canada, [
http://www.amstat.org/meetings/jsm/2010/onlineprogram/AbstractDetails.cfm?abstractid=306921
]